Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
9 participants
INTERVENTIONAL
2022-09-14
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specifically this study examined the acute effect of MitoQ on:
1. cardiopulmonary responses to submax and maximal exercise
2. Energy expenditure and fat/carbohydrate oxidation during sub maximal exercise.
In a double-blind, randomized, placebo controlled, cross-over study design, participants performed 2 experimental trials which differed only in the supplement consumed (MitoQ or Placebo). Participants performed identical exercise protocols which consisted of a series of submaximal workloads followed by a ramp protocol to volitional exhaustion.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging
NCT05872139
MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women
NCT03586414
The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults
NCT02597023
Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity
NCT07244809
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
NCT05878119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Visit 1 consisted of baseline resting measures including blood pressure and blood vessel health, blood biomarkers, and body composition assessments.
Visits 2 and 3 were the acute supplementation intervention(s) with either MitoQ or Placebo in a randomly designed order. These visits included an assessment of blood pressure and blood vessel health and an exercise test on a stationary cycle. There was a minimum of 48-72 hours between trials 2 and 3.
Visit 1
* Participants arrived at the laboratory fasted from all food and drink other than water for at least 12 hours. The following assessments were performed:
* Informed consent and health history questionnaire
* Resting heart rate, handgrip strength, and body composition
* Resting electrocardiogram (ECG)
* Blood biomarkers (Total cholesterol, HDL, LDL-C, and triglycerides as well as fasting blood glucose and HbA1c).
* Blood pressure
Visit 2 \& 3 (performed in a randomized order differing only in the supplement consumed)
Acute supplementation intervention(s)
* The night before both the Placebo and MitoQ trials, participants were asked to eat the same meal at the same time of night and were provided with a standard Ensure shake to consume at 8:00pm the night before each trial.
* Upon arrival, they rested supine for \~10 minutes before consuming supplement (MitoQ or Placebo)
* Following consumption of the supplement or placebo, participants completed a graded aerobic exercise protocol. This test involved riding on a stationary cycle to exhaustion. The total test duration was \~30-45 minutes which included a break to rest between the submax and maximal portions. Heart function was monitored with an electrocardiogram (ECG). A gas analysis cart was used to determine the composition of the air breathed in and out during the test for the determination of substrate oxidation rates and VO2max. Heart rate was measured continuously throughout the exercise protocol from the ECG. Rate of perceived exertion (RPE) was measured every minute and blood pressure (BP) was performed every third minute of the exercise protocol. Additional measures of blood lactate via a finger stick were performed during the exercise protocol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Gelatin capsules
Placebo
Gelatin capsules
MitoQ
Commercially available MitoQ (80mg)
MitoQ
80mg of MitoQ taken in one dose on one occasion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MitoQ
80mg of MitoQ taken in one dose on one occasion.
Placebo
Gelatin capsules
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a resting seated systolic blood pressure (SBP) of less than 160 mmHg and diastolic blood pressure (DBP) less than 100 mmHg
* Nonsmoker
* Body mass index (BMI) less than or equal to 35 kg/m2
* Considered physically inactive defined as participating in \<150 min/week of moderate physical activity or \<75 minutes/week of vigorous activity (ACSM).
Exclusion Criteria
* Individuals that are currently on beta blockers
* diagnosed with type II diabetes will be excluded.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ball State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ball State University
Muncie, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1946841-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.